The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Open accessAbstract
The INK4a-ARF locus encodes two proteins, p16(INK4a) and p19(ARF), that restrain cell growth by affecting the functions of the retinoblastoma protein and p53, respectively. Disruption of this locus by deletions or point mutations is a common event in human cancer, perhaps second only to the loss of p53. Using insect cells infected with baculovirus vectors and NIH 3T3 fibroblasts infected with ARF retrovirus, we determined that mouse p19(ARF) can interact directly with p53, as well as with the p53 regulator mdm2. ARF can bind p53-DNA complexes, and it depends upon functional p53 to transcriptionally induce mdm2 and the cyclin-dependent kinase inhibitor p21(Cip1), and to arrest cell proliferation. Binding of p19(ARF) to p53 requires the ARF N-terminal domain (amino acids 1-62) that is necessary and sufficient to induce cell cycle arrest. Overexpression of p19(ARF) in wild type or ARF-null mouse embryo fibroblasts increases the half-life of p53 from 15 to approximately 75 min, correlating with an increased p53-dependent transcriptional response and growth arrest. Surprisingly, when overexpressed at supra-physiologic levels after introduction into ARF-null NIH 3T3 cells or mouse embryo fibroblasts, the p53 protein is handicapped in inducing this checkpoint response. In this setting, reintroduction of p19(ARF) restores p53's ability to induce p21(Cip1) and mdm2, implying that, in addition to stabilizing p53, ARF modulates p53-dependent function through an additional mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Under most conditions ARF functions as a tumor suppressor by binding and inhibiting Mdm2 activity [47–49].”
From Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis (2012) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells
Gorman, C., Moffat, L. F., & Howard, B. H. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.9.1044 · Cited by 7,674
High-Efficiency Transformation of Mammalian Cells by Plasmid DNA
Chen, C., & Okayama, H. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2745 · Cited by 5,327
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citationTodaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,747
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Flagged first, then by citations
Research works printed but not linked: 10
- M Hollstein, K Rice, M S Greenblatt, T Soussi, R Fuchs, T Sorlie, E Hovig, B Smith-Sorensen, R Montesano, C C Harris Nucleic Acids Res 22, 3551–3555 (1994).
- D Duro, O Bernard, V Della Valle, R Berger, C-J Larsen Oncogene 11, 21–29 (1995).
- L Mao, A Merlo, G Bedi, G I Shapiro, C D Edwards, B J Rollins, D Sidransky Cancer Res 55, 2995–2997 (1995).
- S Stone, P Jiang, P Dayananth, S V Tavtigian, H Katcher, D Parry, G Peters, A Kamb Cancer Res 55, 2988–2994 (1995).
- 10.1128/mcb.13.7.4107-4114.1993 · DOI
- P W Hinds, C A Finlay, R S Quartin, S J Baker, E R Fearon, B Vogelstein, A J Levine Cell Growth Diff 1, 571–580 (1990).
- 10.1128/mcb.7.8.2745-2752.1987 · DOI
- 10.1126/science.256.5058.827 · DOI
- 10.1128/mcb.2.9.1044-1051.1982 · DOI
- G Shaulsky, N Goldfinger, M S Tosky, A J Levine, V Rotter Oncogene 6, 2055–2065 (1991).
Cited by
Sorted by citations
Items 101–200 of 896
The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling
Staudt, L. M., & Davé, S. S. (2005) · Advances in immunology · doi:10.1016/s0065-2776(05)87005-1 · Cited by 262
The E2F transcription factors: key regulators of cell proliferation
Müller, H., & Helin, K. (2000) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(99)00030-x · Cited by 267
Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus
Llanos, S., Clark, P. A., Rowe, J., & Peters, G. G. (2001) · Nature Cell Biology · doi:10.1038/35074506 · Cited by 252
Midgley, C., Desterro, J. M. P., Saville, M. K., Howard, S. F., Sparks, A., Hay, R. T., & Lane, D. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203593 · Cited by 250
Hdac1 and Hdac2 Act Redundantly to Control p63 and p53 Functions in Epidermal Progenitor Cells
LeBoeuf, M. R., Terrell, A. M., Trivedi, S., Sinha, S., Epstein, J. A., Olson, E. N., Morrisey, E. E., & Millar, S. E. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.10.015 · Cited by 246
p53 and ribosome biogenesis stress: The essentials
Golomb, L., Volarević, S., & Oren, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.014 · Cited by 254
Excess β‐catenin promotes accumulation of transcriptionally active p53
Damalas, A., Ben‐Ze'ev, A., Simcha, I., Shtutman, M. S., Martínez-Leal, J. F., Zhurinsky, J., Geiger, B., & Oren, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.11.3054 · Cited by 239
Control of the cell cycle and apoptosis
Lundberg, A. S., & Weinberg, R. A. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00292-0 · Cited by 244
MYC and the Control of ApoptosisPreprint
McMahon, S. B. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014407 · Cited by 240
p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas
Nakamura, M., Watanabe, T., Klangby, U., Asker, C., Wiman, K. G., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00388.x · Cited by 237
Cell proliferation and apoptosis
Guo, M., & Hay, B. A. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00046-0 · Cited by 238
Mechanisms of switching on p53: a role for covalent modification?
Meek, D. W. (1999) · Oncogene · doi:10.1038/sj.onc.1202951 · Cited by 238
p53-Mdm2--the affair that never ends
Alarcon-Vargas, D. (2002) · Carcinogenesis · doi:10.1093/carcin/23.4.541 · Cited by 234
Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1
Asher, G., Lotem, J., Sachs, L., Kahana, C., & Shaul, Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202480499 · Cited by 223
Wang, H., Gao, X., Fukumoto, S., Tademoto, S., Sato, K., & Hirai, K. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199911)181:2 · Cited by 45
p53 and the pathogenesis of skin cancer
Benjamin, C. L., & Ananthaswamy, H. N. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.12.006 · Cited by 223
Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation
Lin, A. W., & Lowe, S. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091100298 · Cited by 215
Fernández, V., Hartmann, E., Ott, G., Campo, E., & Rosenwald, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.019 · Cited by 214
The importance of p53 location: nuclear or cytoplasmic zip code?
O’Brate, A., & Giannakakou, P. (2003) · Drug Resistance Updates · doi:10.1016/j.drup.2003.10.004 · Cited by 214
N-terminal polyubiquitination and degradation of the Arf tumor suppressorPreprint
Kuo, M.-L., den Besten, W., Bertwistle, D., Roussel, M. F., & Sherr, C. J. (2004) · Genes & Development · doi:10.1101/gad.1213904 · Cited by 219
Self-citationMDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation
Jin, Y., Lee, H., Zeng, S. X., Dai, M., & Lu, H. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg600 · Cited by 206
Melanoma genetics and the development of rational therapeutics
Chudnovsky, Y., Khavari, P. A., & Adams, A. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24808 · Cited by 202
Myc proteins as therapeutic targets
Gustafson, W. C., & Weiss, W. A. (2010) · Oncogene · doi:10.1038/onc.2009.512 · Cited by 204
Dynamic Protein Interaction Networks and New Structural Paradigms in Signaling
Csizmók, V., Follis, A. V., Kriwacki, R. W., & Forman-Kay, J. D. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00548 · Cited by 210
Iron and carcinogenesis: from Fenton reaction to target genes
Toyokuni, S. (2002) · Redox Report · doi:10.1179/135100002125000596 · Cited by 207
p53 Signaling and Cell Cycle Checkpoints
Stewart, Z. A., & Pietenpol, J. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000199t · Cited by 204
Pantoja, C., & Serrano, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202880 · Cited by 201
The nucleolus: the magician’s hat for cell cycle tricks
Visintin, R., & Amon, A. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00102-2 · Cited by 196
Genetic and Epigenetic Changes in Human Epithelial Cells Immortalized by Telomerase
Farwell, D. G., Shera, K. A., Koop, J. I., Bonnet, G. A., Matthews, C. P., Reuther, G. W., Coltrera, M. D., McDougall, J. K., & Klingelhutz, A. J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65025-0 · Cited by 196
Juven‐Gershon, T., & Oren, M. (1999) · Molecular Medicine · doi:10.1007/bf03402141 · Cited by 193
Malignant melanoma: modern black plague and genetic black boxPreprint
Chin, L., Merlino, G. T., & DePinho, R. A. (1998) · Genes & Development · doi:10.1101/gad.12.22.3467 · Cited by 195
Ras proteins in the control of the cell cycle and cell differentiation
Crespo, P., & León, J. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000645 · Cited by 190
Hocker, T. L. H., Singh, M. K., & Tsao, H. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.226 · Cited by 196
Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)
Ries, S. J., Brandts, C., Chung, A. S., Biederer, C. H., Hann, B. C., Lipner, E. M., McCormick, F. P., & Korn, W. M. (2000) · Nature Medicine · doi:10.1038/80466 · Cited by 186
Identification of a cryptic nucleolar-localization signal in MDM2
Lohrum, M. A. E., Ashcroft, M. A., Kubbutat, M. H. G., & Vousden, K. H. (2000) · Nature Cell Biology · doi:10.1038/35004057 · Cited by 186
Pagliaro, L., Chen, S., Herranz, D., Mecucci, C., Harrison, C. J., Mullighan, C. G., Zhang, M., Zhu, C. H., Boissel, N., Winter, S. S., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00525-x · Cited by 202
Xing, E. P., Nie, Y., Song, Y., Yang, G., Cai, Y., Wang, L., & Yang, C. S. (1999) · PubMed · Cited by 180
Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Medrano, R. F. V., Hunger, A., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19531 · Cited by 192
Chang, S., Khoo, C. M., Naylor, M. L., Maser, R. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1029903 · Cited by 183
Methylation Silencing and Mutations of the p14ARF and p16INK4a Genes in Colon Cancer
Hirt‐Burri, N., Shaw, P. H., Bouzourène, H., Sordat, I., Sordat, B., Gillet, M., Schorderet, D. F., Bosman, F. T., & Chaubert, P. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780230 · Cited by 181
Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11
Sasaki, M., Kawahara, K., Nishio, M., Mimori, K., Kogo, R., Hamada, K., Itoh, B., Wang, J., Komatsu, Y., Yang, Y. R., et al. (2011) · Nature Medicine · doi:10.1038/nm.2392 · Cited by 179
Self-citationRegulating the p53 system through ubiquitination
Yang, Y., Li, C.-C. H., & Weissman, A. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207411 · Cited by 184
p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination.
Linke, S. P., Sengupta, S., Khabie, N., Jeffries, B. A., Buchhop, S., Miska, S., Henning, W., Pedeux, R., Wang, X. W., Hofseth, L. J., et al. (2003) · PubMed · Cited by 178
Control of p53 ubiquitination and nuclear export by MDM2 and ARF.
Zhang, Y., & Xiong, Y. (2001) · PubMed · Cited by 176
The role of p53 in neuronal cell death
Morrison, R. S., & Kinoshita, Y. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400741 · Cited by 175
Loss of E2F4 Activity Leads to Abnormal Development of Multiple Cellular Lineages
Rempel, R. E., Sáenz-Robles, M. T., Storms, R. W., Morham, S. G., Ishida, S., Engel, A., Jakoi, L., Melhem, M. F., Pipas, J. M., Smith, C. A., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00030-7 · Cited by 172
Genotoxic and non-genotoxic pathways of p53 induction
Pluquet, O., & Hainaut, P. L. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00698-x · Cited by 177
Wadhwa, R. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5468 · Cited by 170
The emerging role of alternative splicing in senescence and aging
Deschênes, M., & Chabot, B. (2017) · Aging Cell · doi:10.1111/acel.12646 · Cited by 172
Nishimura, K., Kumazawa, T., Kuroda, T., Katagiri, N., Tsuchiya, M., Goto, N., Furumai, R., Murayama, A., Yanagisawa, J., & Kimura, K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.055 · Cited by 167
Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas
Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., & Chin, L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2144-2153.2001 · Cited by 166
Otsuka, M., Kato, N., Lan, K., Yoshida, H., Kato, J., Goto, T., Shiratori, Y., & Omata, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000578200 · Cited by 163
Molecular and Genetic Aspects of Lung Cancer
Rom, W. N., Hay, J. G., Lee, T. C., Jiang, Y., & Tchou-Wong, K.-M. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.9908012 · Cited by 163
The genome and epigenome of malignant melanoma
Dahl, C., & Guldberg, P. (2007) · Apmis · doi:10.1111/j.1600-0463.2007.apm_855.xml.x · Cited by 165
Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors
Piepkorn, M. W. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.104687 · Cited by 160
Human ARF binds E2F1 and inhibits its transcriptional activity
Eymin, B., Karayan, L., Seité, P., Brambilla, C., Brambilla, E. M., Larsen, C., & Gazzéri, S. (2001) · Oncogene · doi:10.1038/sj.onc.1204220 · Cited by 161
Mechanisms of asbestos-induced carcinogenesis.
Toyokuni, S. (2009) · PubMed Central · doi:10.18999/nagjms.71.1-2.1 · Cited by 159
Photoprotective effects of green tea polyphenols
Yusuf, N., Irby, C., Katiyar, S. K., & Elmets, C. A. (2007) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/j.1600-0781.2007.00262.x · Cited by 158
Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression
Beverly, L. J., Felsher, D. W., & Capobianco, A. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1664 · Cited by 157
Molecular mechanisms of oxidative stress‐induced carcinogenesis: From epidemiology to oxygenomics
Toyokuni, S. (2008) · IUBMB Life · doi:10.1002/iub.61 · Cited by 152
Verschuren, E. W., Klefström, J. T., Evan, G. I., & Jones, N. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00123-x · Cited by 153
Specificity in the activation and control of transcription factor E2F-dependent apoptosis
Hallstrom, T. C., & Nevins, J. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1831408100 · Cited by 152
Lindström, M. S., Jin, A., Deisenroth, C., Wolf, G. W., & Zhang, Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-06 · Cited by 149
Tumor suppressor p53: regulation and function
Somasundaram, K. (2000) · Frontiers in bioscience · doi:10.2741/somasund · Cited by 155
Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 156
p53 accumulates but is functionally impaired when DNA synthesis is blocked
Gottifredi, V., Shieh, S.-Y., Taya, Y., & Prives, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1036 · Cited by 147
Strategies for manipulating the p53 pathway in the treatment of human cancer
Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/bj3520001 · Cited by 148
(2003) · PubMed · Cited by 147
Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1
Inoue, K., Roussel, M. F., & Sherr, C. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3993 · Cited by 144
Self-citationInk4a/Arf links senescence and aging
Sharpless, N. E. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.06.025 · Cited by 142
Phillips, A. C., & Vousden, K. H. (2001) · APOPTOSIS · doi:10.1023/a:1011332625740 · Cited by 144
Wang, W., Takimoto, R., Rastinejad, F., & El‐Deiry, W. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.2171-2181.2003 · Cited by 144
(2002) · PubMed · Cited by 143
Massively regulated genes: the example of TP53
Hollstein, M. C., & Hainaut, P. L. (2009) · The Journal of Pathology · doi:10.1002/path.2637 · Cited by 149
Kaelin, W. G. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.594 · Cited by 143
The cellular decision between apoptosis and autophagy
Fan, Y., & Zong, W. (2012) · 癌症：英文版 · doi:10.5732/cjc.012.10106 · Cited by 142
Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway
Horn, H. F., & Vousden, K. H. (2008) · Oncogene · doi:10.1038/onc.2008.189 · Cited by 140
Uhrı́nová, S., Uhrı́n, D., Powers, H., Watt, K., Zheleva, D. I., Fischer, P. M., McInnes, C., & Barlow, P. N. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.010 · Cited by 142
Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Kryštof, V., & Uldrijan, S. (2010) · Current Drug Targets · doi:10.2174/138945010790711950 · Cited by 138
PTEN regulation by Akt–EGR1–ARF–PTEN axis
Yu, J., Zhang, S. S., Saito, K., Williams, S., Arimura, Y., Ma, Y., Ke, Y., Baron, V. T., Mercola, D., Feng, G., et al. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.238 · Cited by 139
Multiple facets of junD gene expression are atypical among AP-1 family members
Hernandez, J. M., Floyd, D. H., Weilbaecher, K. N., Green, P. L., & Boris‐Lawrie, K. (2008) · Oncogene · doi:10.1038/onc.2008.120 · Cited by 144
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2
Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El‐Naggar, A. K., & Lozano, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204533 · Cited by 138
p19 Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation
Radfar, A., Unnikrishnan, I., Lee, H., DePinho, R. A., & Rosenberg, N. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13194 · Cited by 140
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date
Bastien, J., McNeill, K. A., & Fine, H. A. (2014) · Cancer · doi:10.1002/cncr.28968 · Cited by 146
Spinophilin: from partners to functions
Sarrouilhe, D., Tommaso, A. D., Métayé, T., & Ladevèze, V. (2006) · Biochimie · doi:10.1016/j.biochi.2006.04.010 · Cited by 137
Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis.
Sato, F., Harpaz, N., Shibata, D., Xu, Y. H., Yin, J., Mori, Y., Zou, T., Wang, S., Desai, K., Leytin, A., et al. (2002) · PubMed · Cited by 136
The p53 network in lung carcinogenesis
Robles, A. I., Linke, S. P., & Harris, C. C. (2002) · Oncogene · doi:10.1038/sj.onc.1205563 · Cited by 138
Current perspectives on the causes of neural tube defects resulting from diabetic pregnancy
Loeken, M. R. (2005) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30056 · Cited by 135
Song, M. S., Song, S. J., Kim, S. Y., Oh, H. J., & Lim, D. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.115 · Cited by 137
Anwar, A., Dehn, D. L., Siegel, D. M., Kepa, J. K., Tang, L. J., Pietenpol, J. A., & Ross, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211981200 · Cited by 132
C ell C ycle D ysregulation in O ral C ancer
Todd, R., Hinds, P. W., Münger, K., Rustgi, A. K., OPITZ, O. G., Suliman, Y., & Wong, D. T. (2002) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130201300106 · Cited by 132
p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2.
Esteller, M., Cordon‐Cardo, C., Corn, P. G., Meltzer, S. J., Pohar, K. S., Watkins, D. N., Capellá, G., Peinado, M. A., Matías‐Guiu, X., Prat, J., et al. (2001) · PubMed · Cited by 132
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models
Vicent, S., Ron, C., Sayles, L. C., Lin, C., Walker, R. G., Gillespie, A. K., Subramanian, A., Hinkle, G., Yang, X., Saif, S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44165 · Cited by 131
Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis
Alt, J. R., Greiner, T. C., Cleveland, J. L., & Eischen, C. M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg133 · Cited by 129
Zilfou, J. T., Hoffman, W. H., Sank, M. J., George, D. L., & Murphy, M. E. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3974-3985.2001 · Cited by 129
Mitochondrial p32 Is a Critical Mediator of ARF-Induced Apoptosis
Itahana, K., & Zhang, Y. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.002 · Cited by 126
Into the heart: The emerging role of the ubiquitin–proteasome system
Willis, M. S., & Patterson, C. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.07.015 · Cited by 125
Zhao, L., Samuels, T. L., Winckler, S., Korgaonkar, C. K., Tompkins, V. S., Horne, M. C., & Quelle, D. E. (2003) · PubMed · Cited by 126
FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of ArfPreprint
Bouchard, C., Lee, S., Paulus-Hock, V., Loddenkemper, C., Eilers, M., & Schmitt, C. A. (2007) · Genes & Development · doi:10.1101/gad.453107 · Cited by 135
(1999) · PubMed · Cited by 123
Metadata
- Authors
- Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Howard Hughes Medical Institute and Departments of Tumor Cell Biology and Biochemistry, St. Jude Children’s Research Hospital, 332 North Lauderdale, Memphis, TN 38105
- Corresponding author
- Sherr, Charles J.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1998-07-07
- Volume
- 95
- Issue
- 14
- Pages
- 8292-8297
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC20969
- OpenAlex
- W2141529421
- Cited by
- 899
- References
- 61
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 2 · 2023: 10 · 2022: 11 · 2021: 15 · 2020: 10 · 2019: 10 · 2018: 12 · 2017: 14 · 2016: 26 · 2015: 21 · 2014: 33 · 2013: 28 · 2012: 34
- FWCI
- 31.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- St. Jude Children's Research Hospital (CA21765)
- American Lebanese Syrian Associated Charities (CA 21765)
- National Institutes of Health (CA21765))
- National Cancer Institute (R01CA063230, CA-71907, CA-63230, CA21765, P30CA021765, P01CA071907)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- p19ARF, p53, MDM2, INK4a/ARF locus, p16INK4a, protein-protein interaction, p53 stabilization, p21 Cip1, cell cycle arrest, p53-dependent transcription, tumor suppressor, p53 DNA binding, N-terminal domain
- MeSH terms
- Animals, Humans, Neoplasm Proteins, Nuclear Proteins, Proteins, Proto-Oncogene Proteins, Retroviridae, Transfection, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, 3T3 Cells, Tumor Suppressor Protein p14ARF, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
